$1.4 Billion is the total value of EcoR1 Capital, LLC's 50 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XNCR | XENCOR INC | $176,381,000 | +19.8% | 4,547,072 | 0.0% | 12.58% | +15.6% | |
| KURA | KURA ONCOLOGY INC | $141,205,000 | +88.0% | 4,608,529 | 0.0% | 10.07% | +81.5% | |
| PRTA | PROTHENA CORP PLC | $94,172,000 | -4.5% | 9,426,640 | 0.0% | 6.72% | -7.8% | |
| ORIC | ORIC PHARMACEUTICALS INC | $66,082,000 | -25.9% | 2,642,218 | 0.0% | 4.71% | -28.4% | |
| RNA | AVIDITY BIOSCIENCES INC | $59,226,000 | -0.4% | 2,103,950 | 0.0% | 4.22% | -3.8% | |
| AKUS | AKOUOS INC | $45,191,000 | +1.6% | 1,975,984 | 0.0% | 3.22% | -1.9% | |
| AMTI | APPLIED MOLECULAR TRANS INC | $36,593,000 | +26.6% | 1,150,000 | 0.0% | 2.61% | +22.2% | |
| GERN | GERON CORP | $33,462,000 | -20.2% | 19,230,769 | 0.0% | 2.39% | -22.9% | |
| RCUS | ARCUS BIOSCIENCES INC | $31,023,000 | -30.7% | 1,810,000 | 0.0% | 2.21% | -33.1% | |
| CYCN | CYCLERION THERAPEUTICS INC | $16,673,000 | +2.9% | 2,742,276 | 0.0% | 1.19% | -0.7% | |
| CNST | CONSTELLATION PHARMCETICLS Icall | $8,104,000 | -32.6% | 400,000 | 0.0% | 0.58% | -34.9% | |
| IRWD | IRONWOOD PHARMACEUTICALS INCcall | $4,498,000 | -12.8% | 500,000 | 0.0% | 0.32% | -15.7% | |
| ACRS | ACLARIS THERAPEUTICS INC | $3,935,000 | +58.6% | 1,531,312 | 0.0% | 0.28% | +53.6% | |
| RPRX | ROYALTY PHARMA PLC | $2,104,000 | -13.3% | 50,000 | 0.0% | 0.15% | -16.2% | |
| FPRX | FIVE PRIME THERAPEUTICS INC | $1,786,000 | -23.0% | 379,945 | 0.0% | 0.13% | -25.7% | |
| RPTX | REPARE THERAPEUTICS INC | $1,539,000 | -0.8% | 50,000 | 0.0% | 0.11% | -4.3% | |
| MGTX | MEIRAGTX HLDGS PLC | $1,255,000 | +5.7% | 94,819 | 0.0% | 0.09% | +1.1% | |
| ICPT | INTERCEPT PHARMACEUTICALS INcall | $1,049,000 | -13.4% | 25,300 | 0.0% | 0.08% | -16.7% | |
| XOMA | XOMA CORP DEL | $957,000 | -4.7% | 50,809 | 0.0% | 0.07% | -8.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KURA ONCOLOGY ORD | 32 | Q3 2023 | 10.5% |
| XENCOR ORD | 25 | Q3 2023 | 12.6% |
| ASSEMBLY BIOSCIENCES ORD | 23 | Q3 2020 | 19.0% |
| FIBROGEN ORD | 22 | Q1 2020 | 12.4% |
| PROTHENA ORD | 20 | Q3 2023 | 28.0% |
| IRONWOOD PHARMA CL A ORD | 20 | Q1 2020 | 13.9% |
| GALAPAGOS NV SPON ADR | 19 | Q3 2023 | 12.0% |
| MORPHIC HOLDING ORD | 18 | Q3 2023 | 8.5% |
| ARCUS BIOSCIENCES ORD | 17 | Q1 2022 | 7.1% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 8.3% |
View EcoR1 Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Mersana Therapeutics, Inc. | July 27, 2023 | 19,364,688 | 16.9% |
| TScan Therapeutics, Inc. | June 05, 2023 | 5,000,000 | 11.7% |
| 2seventy bio, Inc. | February 14, 2023 | 1,143,494 | 3.0% |
| Avidity Biosciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Surface Oncology, Inc. | February 13, 2023 | 3,924,713 | 6.5% |
| Akouos, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Alector, Inc. | February 10, 2023 | 4,056,548 | 4.9% |
| Arcus Biosciences, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Gritstone bio, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Ovid Therapeutics Inc. | February 10, 2023 | 6,117,400 | 8.7% |
View EcoR1 Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-03 |
| SC 13G/A | 2024-04-08 |
| 3 | 2024-03-26 |
| SC 13G/A | 2024-03-26 |
| SC 13G | 2024-03-11 |
| SC 13D | 2024-02-22 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View EcoR1 Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.